STVNStevanato Group Spa
$19.40
$0.03
(0.15%)
EarningsAug 4
Mkt Cap$5.29B
Vol291,132.00
Stevanato Group to Report Second Quarter 2026 Financial Results on August 4, 2026
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the second quarter of 2026 on Tuesday, August 4...
Business Wire
Profound Medical (PROF) Moves 8.2% Higher: Will This Strength Last?
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks
TimesSquare Mid Cap Growth Strategy Downplays Market Fears on Stevanato Group S.p.A. (STVN)
TimesSquare Mid Cap Growth Strategy Downplays Market Fears on Stevanato Group S.p.A. (STVN...
Yahoo! Finance: News
Aurinia (AUPH) Moves 6.5% Higher: Will This Strength Last?
Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks
Is Stevanato Group S.p.A. (STVN) A Good Stock To Buy Now?
Is Stevanato Group S.p.A. (STVN) A Good Stock To Buy Now...
Yahoo! Finance: News
Stevanato Group Introduces Deora, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight Management
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions for the pharmaceutical, biotechnology, and life sciences industries, today introduced Deora, a new proprietary pen injector platform targeting incretin-based therapies, as...
Business Wire
Stevanato Group Announces Results of Ordinary and Extraordinary Shareholders Meeting
Stevanato Group S.p.A. (NYSE: STVN) (the Company), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced that all resolutions proposed to the shareholders at the Ordinary and...
Business Wire
Implied Volatility Surging for Stevanato Stock Options
Investors need to pay close attention to STVN stock based on the movements in the options market lately.
Zacks
Stevanato Group (STVN) Q1 Earnings and Revenues Beat Estimates
Stevanato (STVN) delivered earnings and revenue surprises of +6.56% and +2.32%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Stevanato Group Delivers 7% Revenue Growth (10% at Constant Currency) for the First Quarter of Fiscal 2026
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today...
Business Wire
<
1
2
...
>
HIMS4
2
NOW23
19
CLF3
5Advertisement|Remove ads.